South Georgia Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

South Georgia Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$28K	Buy	+60	New	+$32.2K	0.07%	77

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $677M AUM 27.58% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

South Georgia Capital's REGN Position: Q3 2015 in Review

South Georgia Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2015: 60 shares worth $28K. The stake represents 0.07% of the portfolio and ranks #77 among its holdings.

561 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

South Georgia Capital held 60 shares of Regeneron Pharmaceuticals worth $28K as of Q3 2015.
Regeneron Pharmaceuticals was a new South Georgia Capital position in Q3 2015.
Regeneron Pharmaceuticals made up 0.07% of South Georgia Capital's portfolio in Q3 2015, its #77 holding.
561 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on South Georgia Capital's 13F filing for Q3 2015, filed 10 Nov 2015.